Young girl with psychosis, cognitive failure and seizures

Psychiatric symptoms combined with neurological disturbances should always arouse suspicion that the cause may be organic. We describe a young patient whose examination revealed a recently described condition for which there are precise diagnostics and in many cases effective treatment.

**Imre Önder Slettedal**
Department of Adolescent Mental Health
Centre for Child and Adolescent Mental Health
Oslo University Hospital, Ullevål

**Hilde Margrete Dahl**
Inger Sandvig
Department of Clinical Neurosciences for Children,
Women and Children’s Division
Oslo University Hospital, Ullevål and Rikshospitalet

**Josep Dalmau**
Department of Neurology
University of Pennsylvania
Philadelphia, PA

**Petter Strømme**
petter.stromme@medisin.uio.no
Department of Clinical Neurosciences for Children,
Women and Children’s Division
Oslo University Hospital, Ullevål

* Current address:
Department for Personality Psychiatry
Oslo University Hospital, Ullevål

A girl of school age was admitted after left-sided facial seizures and seizures in her left arm, accompanied by reduced consciousness. In the three weeks leading up to hospitalisation she had been telling her parents that she felt «funny». Her parents and teachers had watched discreet and was largely bedridden.

On admission we found postictal inversion of the left plantar reflex, otherwise equal tempo and power in the extremities. She was disoriented, afibrile, with no neck stiffness or swollen joints, and there was no skin or facial rash. Blood tests showed a leukocyte count of 3.4 · 10⁹/l (4.5–14.0 · 10⁹/l), the C-reactive protein (CRP) level was < 0.5 mg/l (< 10 mg/l), SR 4 mm/l (< 10 mm/l), B-lactate 1.6 mmol/l (< 2.5 mmol/l), B-glucose 4.4 mmol/l (3.5–6.0 mmol/l) and 5 creatinine 45 mmol/l (35–60 mmol/l). The cerebrospinal fluid (CSF) showed a total protein level of 1.0 g/l (< 0.6 g/l), a leukocyte count of 88 · 10⁶/l (< 4 · 10⁶/l), lactate 1.2 mmol/l (< 2.5 mmol/l) and glucose 3.5 mmol/l. The CSF glucose: blood glucose ratio was 0.8 (< 0.67). The cerebrospinal fluid protein electrophoresis was normal. The EEG showed slow rhythms and some epileptic activity, particularly above the right hemisphere (Fig. 1). Magnetic resonance imaging (MRI) of the brain and medulla spinalis (with and without contrast medium) showed no tumour or signal changes in the parenchyma or meninges at T2-weighting.

Clinically and according to EEG, the girl suffered from encephalitis. This was supported by an increase in the total protein level and leukocyte count in the CSF. Metabolic, neurodegenerative and immunological diseases were also considered. Normal concentrations of serum lactate and spinal lactate normally exclude mitochondrial diseases. Normal glucose levels in serum and CSF, and a normal CSF glucose: blood glucose ratio, virtually ruled out a congenital glucose transport defect in the blood-brain barrier (GLUT1 defect). A negative family anamnesis rendered Huntington’s disease unlikely. Systemic lupus erythematosus (SLE) may result in psychiatric and neurological disorders, but normal ESR and the lack of any skin, joint or renal changes made this diagnosis improbable (1). Rasmussen’s encephalitis was also considered. This is an immunologically conditioned epileptic encephalitis with spastic hemiparesis, asymmetric EEG changes and cerebral hemiatrophy (2). The condition often starts with myoclonic seizures while the mental changes occur later, i.e. the opposite order of progression from that found in our patient.

Symptomatic treatment was initiated with Carbamazepine and Chlorpromazine. The patient was afibrile, had a normal blood leukocyte count and normal CRP, which suggested that there was no bacterial infection. Due to the serious clinical picture, the patient was nevertheless given broad-spectrum coverage with Ceftriaxone and Ampicillin administered intravenously against Borrelia and Listeria. Acyclovir was also administered, even though the laboratory data gave no indication of a herpes virus infection. Later microbiological tests showed no indication of infection caused by any of these agents, nor infections caused by Epstein-Barr, varicella, rubella or rabies viruses, or Toxoplasma gondii. Tests for antibodies against Mycoplasma pneumoniae were non-conclusive. Variant Creutzfeldt-Jakob Disease (vCJD) was improbable due to the brief case history and the fact that no signal changes in the brain appeared on the MRI scan (3); also, the CSF tested negative for 14–3–3 protein. This protein is a marker for nerve cell destruction, especially in sporadic Creutzfeldt-Jakob Disease (4). Also, the CSF showed normal values for the glial cell marker GFAP (glial fibrillary acidic protein) and the nerve cell markers NFP (neurofilament protein) and tau protein, which again suggested that there was no form of active brain tissue destruction. Cerebral magnetic resonance spectroscopy (MRS) showed a normal metabolic pattern, which was also an indication against metabolic/ neurodegenerative disease (5).

The patient’s psychiatric symptoms of anxiety, aggressive behaviour and delusions were constantly getting worse, despite treatment with antidepressants. Irrespective of seizures she suffered fits of rage with self-injury and unoccupied laughter. She was suffering from global cognitive failure, dyspraxia, mutism, insomnia, dystonia and catatonia, as well as autonomic nervous system disorders in the form of dilated pupils and tachycardia. She developed difficulties with swallowing and started dribbling, became doubly incontinent, required tube feeding and was largely bedridden.

Given such prominent psychiatric symptoms, combined with pathological findings in the
CASE REPORT

EEG and CSF, limbic encephalitis should be considered. This is a heterogeneous condition caused by autoimmune factors and is often associated with malignant disease (6). In the majority of cases of limbic encephalitis, signal changes will be expected in T2-weighted MRI, but the absence of such changes (as in our patient) does not rule out the diagnosis. Nevertheless, we interpreted the condition to be immune-mediated and treated the patient with steroids and intravenous immunoglobulin from week 3 to week 7 in hospital. Due to unsatisfactory clinical results, plasmapheresis was initiated in week 9. This resulted in immediate improvement followed by gradual recovery. She was discharged after five months and could go back to school eight months after admission. While in hospital and at later outpatient check-ups she was examined for possible malignant disease. Full body CT, MRI, positron emission tomography (PET) and abdominal ultrasound examinations, as well as repeated measurements of tumour markers in serum and urine, were normal. Neuropsychological tests 18 months after admission established that her cognitive functions continued to be weakened. Similar tests 2.5 years after admission showed better results, and after 4.5 years the results were completely normal. The patient is now healthy.

The obvious effect of plasma exchange clearly pointed towards an immune-mediated disease, but specific antibodies or other immunological markers could not be established while the patient was in hospital. Prior to the plasmapheresis, samples of the patient’s CSF and serum were frozen. In the light of reports of a new type of autoimmune encephalitis (7), the frozen samples were sent to the University of Pennsylvania, USA. The analyses showed the presence of NMDA (N-methyl D-aspartate) receptor antibodies in serum and CSF (Fig 2) (8), and we therefore concluded that the diagnosis was anti-NMDA receptor encephalitis.

Discussion

Anti-NMDA receptor encephalitis is not entirely uncommon, and in a prospective study of 203 encephalitis patients in England, nine (4%) were found to have NMDA receptor antibodies (9). As far as we know, our patient is the first case in Norway to have had a diagnosis of anti-NMDA receptor encephalitis verified.

Clinical picture

Anti-NMDA receptor encephalitis differs from limbic encephalitis in that it normally develops in stages, often in five distinct phases: the prodromal phase, the psychotic phase, the non-responsive phase, the hyperkinetic phase and the gradual recovery phase (10, 11). Box 1 gives a summary of the condition’s clinical picture. The majority of patients experience prodromal symptoms similar to those of a viral infection. Within a few days they present with psychiatric manifestations such as anxiety, depression, insomnia, agitation, aggression, personality changes and psychotic symptoms. Loss of short-term memory is common, but can be difficult to establish in small children. Linguistic regression with echolalia, echopraxia and mutism occurs during the non-responsive phase, which is normally followed by motor disturbances and catatonia. Instability of the autonomic nervous system gives temperature and blood pressure fluctuations, central hypoventilation, arrhythmia, sweating, increased saliva production, incontinence and obstipation. Dystonia or seizures

Figure 1 Two weeks after admission, the EEG shows slow activity, most pronounced in the right hemisphere (blue curve) and isolated epileptic discharges (arrow) in the right hemisphere. The patient was medicated with prednisolone, chlorpromazine, risperidone, chloral hydrate and carbamazepine. An earlier examination without medication showed the same slow rhythm, but no epileptiform discharges.

Figure 2 Two neurons in a cell culture from a rat hippocampus, immunostained with cerebrospinal fluid from a patient. The multiple fluorescent green points on the cell surface indicate the presence of NMDA receptor antibodies. The nerve cell nuclei are stained blue using DAPI (4’,6-diamidino-2-phenylindole). The figure is taken from Lancaster et al. (8) and is reproduced with their permission.
often lead to hospitalisation (11). Complex partial or generalised epileptic seizures may occur at any stage of the disease, but most commonly in the early stages. Status epilepticus may also occur (12).

**Pathophysiology**

Figure 3 illustrates the pathophysiological process in which antibodies block postsynaptic glutamatergic excitatory NMDA receptors (13). The clinical stages of the syndrome probably result from increasing antibody-mediated failure of NMDA receptor functions. The trigger factor for the formation of anti-NMDA receptor antibodies is associated with neoplasm in 60% of cases; the remainder of cases are considered idiopathic (11).

**Examination and diagnosis**

The EEG pattern is almost always pathological and shows a slow rhythm combined with epileptic activity (14). As in the case of our patient (Fig 1), the rhythm change can occur relatively unilaterally (15). In the majority of cases, there are pathological findings in the CSF; these include a moderately increased leukocyte count and/or a slightly increased total protein level, and sometimes oligoclonal bands (11). MRI scans of the central nervous system show pathological changes in half the patients, and T2-weighted examination or FLAIR (fluid attenuated inversion recovery) examination can show modest hyperintensity in the temporal lobes, the cerebellum, the basal ganglia, the brain stem and sometimes the spinal cord (11). The diagnosis can be verified by findings of specific NMDA receptor antibodies in the CSF and serum. (Analyses are performed at Haukeland University Hospital’s neurology and rheumatology laboratory in Bergen.) Patients should be examined with a view to the presence of an underlying tumour. The incidence of neoplasm increases in patients over 18 years of age. In women, teratoma of the ovary is the most frequently associated tumour. Examinations relevant for patients with suspected anti-NMDA encephalitis are summarised in Box 2.

**Differential diagnoses**

Anti-NMDA receptor encephalitis is probably the second most common immune-mediated type of encephalitis, second only to acute disseminated encephalomyelitis (ADEM) which is typically characterised by high signal areas in the brain and spinal cord in T2-weighted MRI scans (16). Other types of encephalitis are caused by antibodies against a number of other receptors, and ion...
channels; their manifestations may overlap with anti-NMDA receptor encephalitides (17). Some patients suffering from the early stages of anti-NMDA receptor encephalitis are first admitted for psychiatric assessment and are treated with psycho-pharmaceuticals (18). However, psycho-pharmaceuticals will not stop the development of the disease, which can progress with manifestations that are confusingly similar to malignant neuroleptic syndrome with muscle rigidity, catatonia and autonomic disorders (19). NMDA receptor antibodies were established in several patients who had previously been diagnosed with encephalitis lethargica, a condition characterised by psychiatric symptoms, insomnia and extra-pyramidal motor disturbances (20). Some children who previously have been assumed to suffer from late-onset autism or unusually early manifestations of schizophrenia have turned out to be suffering from anti-NMDA receptor encephalitis (21).

Treatment and prognosis
Treatment consists of immune therapy with corticosteroids, intravenous immunoglobulin and/or plasmapheresis (8, 11). If the effect is unsatisfactory, rituximab or cyclophosphamide should be considered. Any tumour should be removed. With this treatment strategy approximately 75% achieve considerable improvement; the others suffer severe neurological damage or die (11). The disease is fatal in approximately 4% of cases. The most common causes of death are arrhythmia, status epilepticus, tumour progression and complications suffered during intensive care (11, 14). Improvement in disease symptoms occurs in the opposite order of its clinical phases. Symptomatic treatment includes anti-epileptics and medication for insomnia as well as psychiatric and autonomic symptoms. Anti-NMDA receptor encephalitis normally requires hospitalisation for several months, followed by physical and cognitive rehabilitation. Recovery may take up to three years (11). Early and aggressive treatment is important for optimal cognitive functioning (22). Social behaviour and executive functions are the last to normalise. Amnesia for the illness is common. Relapse occurs in up to 25% of patients and immunosuppression is recommended for a year after the initial treatment has concluded (11).

Addendum
After the work on this article had commenced, a patient with psychosis and catatonia was transferred to the Paediatric Department due to suspected Neuroleptic Malignant Syndrome. The EEG clearly showed slow rhythm activity, but no epileptic discharges. The serum and CSF tested positive for NMDA receptor antibodies.

The patient and the patient’s parents have given their consent to the publication of this article. The patient referred to in the Addendum has also consented.

We would like to thank Inger Anette Hynås Hovden at Oslo University Hospital Ullevål’s Laboratory of Clinical Neurophysiology for interpreting the EEGs.

Imer Ønder Slettedal (born 1976) is a medical doctor specialising in child and adolescent psychiatry. The author has completed the ICMJE form and declares no conflicts of interest.

Hilde Margrete Dahl (born 1966) is a Paediatrician and a Senior Consultant in adolescent psychiatry. The author has completed the ICMJE form and declares no conflicts of interest.

Inger Sandvig (born 1953) is a Paediatrician and a Senior Consultant specialising in epilepsy. The author has completed the ICMJE form and declares no conflicts of interest.

Josep Dalmau (born 1953) is a Research Professor at ICREA-IDIBAPS, Hospital Clinic, University of Barcelona, and an Adjunct Professor of neurology at the University of Pennsylvania’s Department of Neurology. Neuromyelitis is his field of special interest. The author has completed the ICMJE form and declares the following conflicts of interest: He receives royalties from Up-To-Date, and from patents for the utilisation of Ma2 and NMDA receptors in antibody analyses. He has received grant awards from Euroimmun, the National Institute of Health (RO1NS077851 and RO1MH094741), the National Cancer Institute (RO1CA89054), and Fundació la Marató de TV3, the National Institute of Health (RO1NS077851 and RO1MH094741), and Fundació la Marató de TV3, and he has been awarded the McKechnie Neuroscience of Brain Disorders Award.

Petter Stramme (born 1951) is a Paediatrician, Senior Consultant and Professor specialising in neurodegeneration and the genetic causes of intellectual disability. The author has completed the ICMJE form and declares no conflicts of interest.

References